摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(6-methoxypyridin-3-yl)-2-methylbenzenesulfonamide | 680591-13-3

中文名称
——
中文别名
——
英文名称
N-(6-methoxypyridin-3-yl)-2-methylbenzenesulfonamide
英文别名
N-(6-methoxypyridin-3-yl)-2-methylbenzene-1-sulfonamide
N-(6-methoxypyridin-3-yl)-2-methylbenzenesulfonamide化学式
CAS
680591-13-3
化学式
C13H14N2O3S
mdl
——
分子量
278.332
InChiKey
YOSUCWMJWWAHDI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    435.5±55.0 °C(Predicted)
  • 密度:
    1.312±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于氯仿、DCM、乙酸乙酯

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    76.7
  • 氢给体数:
    1
  • 氢受体数:
    5

SDS

SDS:de92dd88f9e871325b7e1ae764a7b9a1
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors
    摘要:
    EMPA is a selective antagonist of orexin 2 (OX2) receptors. Previous literature with [H-3]-EMPA suggest that it may be used as an imaging agent for OX2 receptors; however, brain penetration is known to be modest. To evaluate the potential of EMPA as a PET radiotracer in non-human primate (as a step to imaging in man), we radiolabeled EMPA with carbon-11. Radiosynthesis of [C-11] N-ethyl-2-(N-(6-methoxypyridin- 3-yl)-2-methylphenylsulfonamido)-N-(pyridin-3-ylmethyl) acetamide ([C-11] EMPA), and evaluation as a potential PET tracer for OX2 receptors is described. Synthesis of an appropriate non-radioactive O-desmethyl precursor was achieved from EMPA with sodium iodide and chlorotrimethylsilane. Selective O-methylation using [C-11] CH3I in the presence of cesium carbonate in DMSO at room temp afforded [C-11] EMPA in 1.5-2.5% yield (non-decay corrected relative to trapped [C-11] CH3I at EOS) with >= 95% chemical and radiochemical purities. The total synthesis time was 34-36 min from EOB. Studies in rodent suggested that uptake in tissue was dominated by nonspecific binding. However, [C-11] EMPA also showed poor uptake in both rats and baboon as measured with PET imaging. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.03.079
  • 作为产物:
    参考文献:
    名称:
    SULFONYLAMINO-ACETIC ACID DERIVATIVES
    摘要:
    本发明涉及新型磺酰氨基乙酸衍生物及其作为制备药物组成的活性成分的用途。本发明还涉及相关方面,包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物,特别是它们作为促进睡眠的药物的用途。
    公开号:
    US20070244156A1
点击查看最新优质反应信息

文献信息

  • Sulfonylamino-acetic acid derivatives
    申请人:Aissaoui Hamed
    公开号:US20060014783A1
    公开(公告)日:2006-01-19
    The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    本发明涉及一种新型磺酰氨基乙酸衍生物及其作为制备药物组合物中的活性成分的用途。本发明还涉及相关方面,包括制备这些化合物的过程,含有其中一种或多种化合物的药物组合物,特别是它们作为促进睡眠的药物和促进睡眠的药物。
  • SULFONYLAMINO-ACETIC ACID DERIVATIVES
    申请人:Aissaoui Hamed
    公开号:US20070244156A1
    公开(公告)日:2007-10-18
    The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
    本发明涉及新型磺酰氨基乙酸衍生物及其作为制备药物组成的活性成分的用途。本发明还涉及相关方面,包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物,特别是它们作为促进睡眠的药物的用途。
  • Aminoethane Sulfonamide Orexin Receptor Antagonists
    申请人:Coleman Paul J.
    公开号:US20090258903A1
    公开(公告)日:2009-10-15
    The present invention is directed to aminoethane sulfonamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及氨基乙磺酰胺化合物,其是促进睡眠的荷尔蒙受体拮抗剂,可用于治疗或预防神经和精神障碍以及涉及荷尔蒙受体的疾病。该发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及荷尔蒙受体的疾病中使用这些化合物和组合物。
  • WO2007/19234
    申请人:——
    公开号:——
    公开(公告)日:——
  • SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:EP1554239A2
    公开(公告)日:2005-07-20
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐